NCT07339202 Preoperative Hemodialysis Timing in Patients With End-Stage Kidney Disease: The POD-ESKD Pilot Trial
| NCT ID | NCT07339202 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Stanford University |
| Condition | Perioperative Management |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2026-05-27 |
| Primary Completion | 2027-09-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2026-05-27 with a primary completion date of 2027-09-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to evaluate the feasibility of two different preoperative hemodialysis schedules for people with end-stage kidney disease (ESKD) who undergo surgical procedures. The main questions it aims to answer are: Is it feasible to randomize participants with ESKD undergoing nonemergent surgical procedures to same-day hemodialysis versus no same-day hemodialysis? Is it safe to randomize participants with ESKD undergoing nonemergent surgical procedures to same-day hemodialysis versus no same-day hemodialysis? Researchers will compare the two hemodialysis schedules to see if the scheduling and safety profiles are the same. Participants will: Answer questions about their health up to 4 weeks before and 4 weeks after the surgical procedure. Receive hemodialysis on the day of the surgical procedure or not, depending on the study treatment assignment.
Eligibility Criteria
Inclusion Criteria: 1. Patient is willing to comply with all study procedures for the duration of the study 2. Patient has a diagnosis of ESKD 3. Patient initiated hemodialysis at least 90 days prior to the planned surgical procedure 4. Patient is treated with a stable hemodialysis schedule, defined as an average of 2.5- 3.5 hemodialysis sessions per week in the preceding 4 weeks prior to surgery 5. Patient is scheduled to undergo nonemergent surgical procedures in the Stanford Health Care system. This includes (but is not limited to): * Fistula or graft creation, revision, or removal * Fistulogram * Peritoneal dialysis catheter placement or revision * Lower extremity angiogram (including femoral and iliac vessels) * Lower extremity bypass (including femoral and iliac vessels) * Lower extremity amputation * Lower extremity endarterectomy (including femoral and iliac vessels) Of note, this list of procedures is not exhaustive and other procedures may be considered that meet inclusion criteria and no exclusion criteria, in consultation with the treatment teams involved. Exclusion Criteria: 1. Patient is pregnant 2. Patient is a prisoner 3. Patient is \< 18 years old 4. The treating clinicians determine that the patient's clinical condition necessitate a specific approach to surgical scheduling or preoperative hemodialysis
Contact & Investigator
Vikram Fielding-Singh, MD, JD
PRINCIPAL INVESTIGATOR
Stanford University
Frequently Asked Questions
Who can join the NCT07339202 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Perioperative Management. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07339202 currently recruiting?
Yes, NCT07339202 is actively recruiting participants. Visit ClinicalTrials.gov or contact Stanford University to inquire about joining.
Where is the NCT07339202 trial being conducted?
This trial is being conducted at Stanford, United States.
Who is sponsoring the NCT07339202 clinical trial?
NCT07339202 is sponsored by Stanford University. The principal investigator is Vikram Fielding-Singh, MD, JD at Stanford University. The trial plans to enroll 30 participants.